Arvinas Q3 net loss $64M, cash $1B; vepdegestrant Phase 3 on track for 2H 2024

ARVINAS, INC.

2023-Q3 EPS reported -$3.97 revenue$121,600,000

Q3 2023 net loss $64.0M vs $66.2M prior year; revenue $34.6M from collaborations.
Cash, cash equivalents and marketable securities $1.004B as of Sept 30, 2023; runway into 2026.
VERITAC-2 Phase 3 trial of vepdegestrant in 2L+ ER+/HER2- breast cancer enrollment ongoing; top-line data 2H 2024.
Prioritized ARV-766 over bavdegalutamide for Phase 3 in mCRPC based on broader efficacy and superior tolerability.
Plan to submit two IND/CTA applications for BCL6 (oncology) and LRRK2 (neuroscience) PROTAC degraders by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

ARVINAS, INC. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-23-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.